BCL2/MDM2抑制剂组合对急性髓系白血病有效。
BCL2/MDM2 Inhibitor Combo Effective in AML.
出版信息
Cancer Discov. 2019 Feb;9(2):156. doi: 10.1158/2159-8290.CD-NB2019-003. Epub 2019 Jan 15.
Abstract
The BCL2 inhibitor venetoclax plus the MDM2 inhibitor idasanutlin may be effective in treating relapsed/refractory acute myeloid leukemia. In a phase Ib trial, 35.9% of patients who received the combination had a response; side effects were manageable.
摘要
BCL2抑制剂维奈托克联合MDM2抑制剂idasanutlin可能对治疗复发/难治性急性髓系白血病有效。在一项Ib期试验中，接受联合治疗的患者中有35.9%产生了反应；副作用可控。
Zotero 插件